Neutropenia  >>  Erbitux (cetuximab) 
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
NCT02101034: PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
1/2
96
US
Cetuximab, Erbitux®, PD 0332991, palbociclib
Washington University School of Medicine, Pfizer
Carcinoma, Squamous Cell of Head and Neck
06/20
11/23
NCT02671435 / 2016-000662-38: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Hourglass Jan 2021 - Dec 2022 : From trial in combination with monalizumab for solid tumors
Hourglass Jan 2021 - Dec 2021 : Data from P2 expansion cohort 3 of P1/2 trial in combination with monalizumab and cetuximab for SCCHN
Checkmark Combination trial with monalizumab at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Combination trial with monalizumab at ASCO 2018 [screenshot]
Checkmark Combination study with NKG2A
More
Active, not recruiting
1/2
383
Europe, Canada, US, RoW
Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
MedImmune LLC
Advanced Solid Tumors
10/21
09/24

Download Options